Description of Invention:
Kaposi's Sarcoma (KS) is the most common malignancy in patients with acquired immunodeficiency syndrome (AIDS) in the U.S. The present invention makes available cell lines that provide a means for testing anti-Kaposi's Sarcoma therapies in vitro, or a model animal system. The invention allows therapies to be tested and dosages to be optimized prior to testing in humans. The cell line also provides a means of developing novel antitumor therapies and facilitates studies of factors that influence the development and metastasis of malignancies.
Inventors:
Y Iskandar-Lunardi (NCI) RC Gallo (NCI)
Patent Status:
DHHS Reference No. E-116-1992/0 --
U.S. Patent No. 5,569,602 issued 29 Oct 1996
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-Other Cancer -Diagnostics Cancer -Research Materials
For Additional Information Please Contact: Jasbir (Jesse) S. Kindra J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5559
Email: kindraj@mail.nih.gov
Fax: (301) 402-0220
